bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code (รหัสการทดสอบ):
090-30-1770-01

Order Name (ชื่อการทดสอบ):
Free PSA

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Turnaround Time (ระยะเวลารอผล):
Specimen collected to reported within 2:00 hours (120 mins)
 
Useful For (ประโยชน์การทดสอบ):
Determination of Free Prostate Specific Antigen (PSA) in human serum. 

The ARCHITECT Free PSA assay is intended to be used in conjunction with the ARCHITECT Total PSA assay in men aged 50 years or older with Total PSA values between 4 and 10 ng/mL and DRE
non-suspicious for cancer to determine the % Free PSA value.

Used as an aid in discriminating between prostate cancer and benign disease. 
 
Methodology (วิธีการทดสอบ):
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
AliasesName (ชื่อเรียกอื่นๆ) :
Free Prostate-Specific Antigen
 
 
 
Test Code (รหัสการทดสอบ):
090-30-1770-01

Order Name (ชื่อการทดสอบ):
Free PSA

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Serum, minimum volume 1 mL
 
Sub Mission Container (ภาชนะส่งตรวจ):
Plastic vial
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Hemolysis: 4+ reject
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
Specimen Type Temperature Time
Serum (keep in original tube) Refrigerated: 2oC to 8oC 3 hours
Serum Refrigerated, 2oC to 8oC 1 days
Frozen, -20oC 7 days
 
 
 
Test Code (รหัสการทดสอบ):
090-30-1770-01

Order Name (ชื่อการทดสอบ):
Free PSA

 
Method detail (วิธีการทดสอบ):
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
Schedule (ตารางการทดสอบ):
Tested daily (24 hours)
 
Turnaround Time (ระยะเวลารอผล):
Specimen collected to reported within 2:00 hours (120 mins)
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time (ระยะเวลาเก็บสิ่งส่งตรวจ):
5 days
 
 
 
Test Code (รหัสการทดสอบ):
090-30-1770-01

Order Name (ชื่อการทดสอบ):
Free PSA

 
 
Clinical Information (ข้อมูลทางคลินิก):
Prostate specific antigen (PSA), a member of the human kallikrein gene family, is a serine protease with chymotrypsin-like activity. The mature form of PSA is a single chain glycoprotein of 237 amino acids containing 7-8% carbohydrate as a single N-linked oligosaccharide side chain. PSA has a molecular weight of approximately 30,000 daltons. The major site of PSA production is the glandular epithelium of the prostate. PSA produced by the prostate is secreted into the seminal fluid in high concentrations. PSA is also present in urine and serum.

The function of PSA is the proteolytic cleavage of gel forming proteins in the seminal fluid resulting in liquefaction of the seminal gel and increased sperm mobility. Low levels of PSA are found in the blood as a result of leakage of PSA from the prostate gland. Increasing levels of PSA are associated with prostatic pathology; including prostatitis, benign prostatic hyperplasia (BPH), and cancer  of the prostate. PSA occurs in three major forms in blood. The major immunodetectable form is PSA complexed with the serine protease
inhibitor, alpha-1-antichymotrypsin (PSA-ACT). Uncomplexed, or Free PSA, is the other immunodetectable form of PSA in serum.

The majority of Free PSA'in serum appears to be an inactive form that cannot complex with protease inhibitors and may be either a PSA zymogen or an enzymatically-inactive, cleaved form of PSA. A third form of PSA, a complex with alpha-2-macroglobulin (AMG), is not detectable with current immunoassays for PSA due to the engulfment and subsequent masking of PSA epitopes by the alpha2-macroglobulin molecule.
lmmunoassays have been designed to detect Free PSA, PSA-ACT complex, and Total PSA (immunodetectable forms: e.g., Free PSA and PSA-ACT) .

Using these types of assays, the proportion of Free PSA in the serum was found to be significantly higher
in patients with BPH than in patients with prostate cancer (p < 0.00001) . The proportion, or percent, of Free PSA determined by comparing the concentration of Free PSA to the concentration of Total PSA has been proposed as a way to improve the discrimination between BPH and prostate cancer, especially in those men with intermediate levels of total serum PSA.
 
Clinical Reference (เอกสารอ้างอิง):
Manufacturer’s Reagent package insert Architect Free PSA, August 2017, Abbott Ireland, Diagnostics Division Finisklin Business Park Sligo, Ireland.